GlaxoSmithKline Biologicals
Rixensart, Antwerpen, Belgium
Purpose
to accelerate the development of new vaccines for high priority diseases such as malaria, tuberculosis (TB), and HIV by permitting external investigators access to Adjuvant Systems that have been properly formulated and thus “optimized” for
Division
Global Health
Date
November 2014
Region Served
GLOBAL
Committed amount
$1,199,441
Grant topic
Discovery and Translational Sciences
Duration (months)
47
Grantee location
Rixensart, Antwerpen, Belgium
Related work
More about our financials
Our story
Learn about the origins of the foundation and the values that drive our work.
Our work
Learn about where we work around the globe and the programs we’ve created to address urgent issues in global health, global development, and education.
How we work
We are focused on results. Those that can be measured. And those measured in ways beyond numbers.